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would be an important step toward personalized blood trans-
fusion. The meta-analysis by Hovaguimian and Myles.5 has 
made important progress toward this goal.
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In Reply:
We would like to thank Drs. Warner, Qiu, and colleagues for 
their valuable inputs regarding our systematic review.1
Dr. Warner rightly points out that CIs crossing the 
equality line correspond to nonsignificant results and sug-
gests that the wording of our findings may have failed to 
reflect this lack of statistical significance. Although we agree 
that “borderline” results (i.e., where one end of the CI just 
overlaps the null value) should be interpreted with cau-
tion, it is worth to note that the Cochrane Collaboration 
discourages formulations such as “nonsignificant” or “not 
statistically significant,” since these terms are commonly 
misinterpreted as an indication that “the intervention has 
no effect.”2 Although some authors would describe such 
findings as a “tendency” or a “trend” toward an effect, we 
opted for a more moderate wording (i.e., using formula-
tions such as “seemed to” or “possible increase”), as sug-
gested elsewhere.3 As for the interpretation of borderline 
findings, it might help to remember that the true effect is 
more likely to lie around the point estimate (i.e., around the 
risk ratio) than at the margins of the CI.3 The traditionally 
significant P < 0.05 may well be suitable for testing efficacy, 
but CIs rather than hypothesis testing are preferred when 
testing safety, equivalence, or noninferiority.4
A second concern of Dr. Warner’s is that our analysis did 
not include transfusion-related pulmonary complications, 
which may have resulted in an underestimation of potential 
harmful effects associated with liberal transfusion strategies. 
The rationale behind the exclusion of pulmonary complica-
tions was mainly related to the quality of the reported data 
in the original trials: in most studies, there was no distinc-
tion between transfusion-related events (such as acute lung 
injury or pulmonary edema due to circulatory overload) and 
events secondary to inadequate oxygen supply, such as left-
sided heart failure due to myocardial infarction. Including 
outcomes with opposite etiologies could have resulted in a 
dilution of the intervention effects.
Qui et al. highlight a potential issue encountered in trials 
addressing transfusion strategies, i.e., the fact that heterogene-
ity in hemoglobin levels within individual treatment groups 
may potentially dilute treatment effects. Their concern is 
based on the assumption that patients assigned to a restrictive 
strategy who received blood transfusions would eventually 
have the same (posttransfusion) hemoglobin levels as those 
from the liberal group. A similar issue may occur if some 
patients assigned to a restrictive strategy never developed 
anemia (i.e., perioperative hemoglobin levels maintained in 
the range of the liberal group). This could indeed lead to an 
underestimation of adverse events, since only a small fraction 
of patients assigned to a restrictive strategy would truly be at 
risk of developing anemia-related complications. To address 
this potential source of heterogeneity, Qui et al. propose 
to stratify the analysis according to hemoglobin levels (see 
table 1, which provides a detailed description of hemoglo-
bin levels across studies). Although the idea is very elegant, 
such exploratory analyses should be carried out with caution, 
since the quality of the reported data remains limited (data 
not extractable, heterogeneity in the frequency or duration 
of hemoglobin measurements, or use of inadequate statistics 
[e.g., Student’s t test for data correlated over time]). It is also 
worth noting that the randomized design used in the origi-
nal studies tends to protect from bias and residual confound-
ing. We certainly agree that large, well-designed randomized 
controlled trials are still needed to fully explore the effects 
of transfusion strategies and eagerly await the results of the 
ongoing Transfusion Requirements in Cardiac Surgery-III 
trial (NCT 02042898).
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